PSMB6 Inhibitors

The above list comprises a range of chemicals that inhibit the proteasome complex, a cellular machinery that plays a crucial role in protein degradation and turnover. PSMB6, as part of this complex, is indirectly targeted by these inhibitors. These compounds vary in their specificity, mode of action, and reversibility, offering a diverse set of tools to modulate proteasome function. Bortezomib, Carfilzomib, Ixazomib, and related compounds primarily inhibit the chymotrypsin-like activity of PSMB5, one of the most active sites in the proteasome complex. This inhibition can indirectly affect PSMB6, as the functional integrity of the proteasome depends on the coordinated activity of its various subunits.

Marizomib and Salinosporamide A are broad-spectrum proteasome inhibitors. They act on multiple active sites within the proteasome, potentially affecting PSMB6's function as part of the larger complex. Oprozomib, Delanzomib, and MLN9708 are oral proteasome inhibitors that offer more convenient administration routes while still targeting the proteasome complex. Lactacystin is a specific inhibitor known for its unique mode of action, binding irreversibly to the active site threonine of the proteasome. Its effect on PSMB5 may indirectly influence the activity of PSMB6. ONX 0914 and CEP-18770 are interesting for their roles in targeting the immunoproteasome, a specialized form of the proteasome complex found in immune cells. While their primary targets are not PSMB6, their inhibition of closely related proteasome subunits suggests potential indirect effects on PSMB6. PR-171, structurally related to Carfilzomib, further exemplifies the approach of designing inhibitors based on known effective structures, aiming to target the proteasome complex and, by extension, potentially influence PSMB6.